Cancer Biomarker Global Market Opportunities And Strategies To 2033

Description

Cancer biomarkers refer to biological molecules found in blood, other body fluids or tissues that are indicative of the presence of cancer in the body. These biomarkers can be proteins, genetic material or other types of molecules that provide critical information about the health status of an individual, especially in the context of cancer.

The cancer biomarker market consists of sales, by entities (organizations, sole traders and partnerships), of diagnostic products and services related to cancer biomarkers that are utilized by healthcare professionals and researchers for a variety of purposes, including the early detection of cancer, monitoring the progression of the disease, evaluating the effectiveness of treatment and predicting prognosis and the likelihood of cancer recurrence. They play a crucial role in personalized medicine, allowing for tailored treatment plans based on the specific biomarkers present in an individual's cancer.

The global cancer biomarker market was valued at $10,473.92 million in 2018 which grew till 2023 at a compound annual growth rate (CAGR) of more than 13.50%.

Increase In Demand For Personalized Medicine

An increase in demand for personalized medicine propelled the growth of the cancer biomarker market. Personalized medicine, also known as precision medicine or individualized medicine, is an approach to medical care that aims to tailor treatments and interventions to the specific characteristics of each patient. Personalized medicine seeks to customize medical care to each patient's unique attributes, including genetic composition, biomarker profile and other variables. When compared to conventional, one-size-fits-all methods, targeted medicines can be developed with greater efficacy and fewer adverse effects thanks to the use of biomarkers in the identification of specific molecular targets for therapy. For instance, in October 2022, according to the Personalized Medicine Coalition, a US-based organization that represents scientists, patients and providers, promoting the understanding and adoption of personalized medicine to benefit patients and the healthcare system) estimated that more than 75,000 genetic testing products and 300 personalized medicines are on the market for people with multiple types of cancers, genetic rare diseases and a range of chronic and infectious diseases. Additionally, in 2022, according to the Personalized Medicine Coalition (PMC), a US-based company that advocates for personalized medicine, personalized medicines will account for 34% of new drug approvals by the US Food and Drug Administration in 2022 and have accounted for at least 25% of approvals in each of the previous eight years. Therefore, the increase in demand for personalized medicine supported the growth of the cancer biomarker market during the historic period.

Focus On AI Solution For Advancing Cancer Diagnostics And Cancer Drugs

Major companies are focused on an AI-driven solution for advancing cancer diagnostics utilizes machine learning algorithms to analyze medical imaging data such as X-rays, MRIs, CT scans and histopathology slides. These algorithms can detect subtle patterns and anomalies indicative of cancerous growths, enabling earlier and more accurate diagnoses. For instance, in September 2023, Ibex Medical Analytics, an Israel-based medical technology manufacturing company and leader in AI-powered cancer diagnostics, announced Galen Breast HER2, an artificial intelligence (AI) solution enhancing accurate and reproducible HER2 scoring in breast cancer patients. Galen Breast HER2 employs AI to detect invasive tumor areas and quantify HER2 expression into standard categories, aiding in patient identification for targeted therapies. The solution offers pathologists a comprehensive AI platform for analyzing H&E and IHC-stained slides, supporting quick and consistent HER2 scoring and enabling full review of breast biopsies with automated quantification of additional biomarkers.

The global cancer biomarker market is highly concentrated, with a few large players dominating in the market. The top ten competitors in the market made up to 51.6% of the total market in 2022

Cancer Biomarker Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global cancer biomarker market as it emerges from the COVID-19 shut down.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for cancer biomarker? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The cancer biomarker market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider cancer biomarker market; and compares it with other markets.

The report covers the following chapters

Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by biomarkers type, by profiling technologies, by cancer type and by application.
Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
Macro-Economic Scenario- The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the cancer biomarker market.
Global Market Size And Growth- Global historic (2018-2023) and forecast (2023-2028, 2033F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
Regional And Country Analysis- Historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison by region and country.
Market Segmentation- Contains the market values (2018-2023) (2023-2028, 2033F) and analysis for each segment by biomarkers type, by profiling technologies, by cancer type and by application in the market. Historic (2018-2023) and forecast (2023-2028) and (2028-2033) market values and growth and market share comparison by region market.
Regional Market Size and Growth- Regional market size (2023), historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
Competitive Dashboard- Briefs on competitive dashboard of major players.
Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
Conclusions And Recommendations- This section includes recommendations for cancer biomarker providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

1) By Biomarkers Type: Protein Biomarkers; Genetic Biomarkers; Other Cancer Biomarkers
2) By Profiling Technologies: Omics Technologies; Imaging Technologies; Immunoassay Bioinformatics; Cytogenetics
3) By Application: Diagnostics; Research and Development; Prognostics; Risk Assessment; Other Applications
4) By Cancer Type: Cervical Cancer; Breast Cancer; Lung Cancer; Brain and Central Nervous System Cancer; Kidney Cancer; Colorectal Cancer; Prostate Cancer; Ovarian Cancer; Stomach Cancer; Other Cancers
Companies Mentioned: Roche Diagnostics; Novartis AG; Illumina; Hologic Inc.; Thermo Fisher Scientific
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; Italy; Spain; UK; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time-series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; cancer biomarker indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Product Code: o&s1203

1 Executive Summary

1.1 Cancer Biomarker - Market Attractiveness And Macro economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

6.1 General Market Definition
6.2 Summary
6.3 Cancer Biomarker Market Definition And Segmentation
6.4 Market Segmentation By Biomarkers Type
- 6.4.1 Protein Biomarkers
- 6.4.2 Genetic Biomarkers
- 6.4.3 Other Cancer Biomarkers
6.5 Market Segmentation By Profiling Technologies
- 6.5.1 Omics Technologies
- 6.5.2 Imaging Technologies
- 6.5.3 Immunoassays
- 6.5.4 Bioinformatics
- 6.5.5 Cytogenetics
6.6 Market Segmentation By Cancer Type
- 6.6.1 Cervical Cancer
- 6.6.2 Breast Cancer
- 6.6.3 Lung Cancer
- 6.6.4 Colorectal Cancer
- 6.6.5 Prostate Cancer
- 6.6.6 Brain And Central Nervous System Cancer
- 6.6.7 Kidney Cancer
- 6.6.8 Ovarian Cancer
- 6.6.9 Stomach Cancer
- 6.6.10 Other Cancer Types
6.7 Market Segmentation By Application
- 6.7.1 Diagnostics
- 6.7.2 Research And Development
- 6.7.3 Prognostics
- 6.7.4 Risk Assessment
- 6.7.5 Other Applications

7 Major Market Trends

7.1 Focus On AI Solution For Advancing Cancer Diagnostics And Cancer Drugs
7.2 Strategic Partnerships And Collaborations To Strengthen Market Position
7.3 Establishment Of Centre Of Excellence To Develop Biomarkers For Early Detection Of Cancer
7.4 Developments In Blood-Borne Circulating Biomarkers For Cancer Detection
7.5 Focus On Development Of Radioligand Therapy For Cancer Biomarker

8 Cancer Biomarker Market - Macro Economic Scenario

8.1 COVID-19 Impact On The Cancer Biomarker Market
8.2 Impact Of The War In Ukraine On The Cancer Biomarker Market
8.3 Impact Of High Inflation On The Cancer Biomarker Market

9 Global Market Size and Growth

9.1 Market Size
9.2 Historic Market Growth, 2018 - 2023, Value ($ Million)
- 9.2.1 Market Drivers 2018 - 2023
- 9.2.2 Market Restraints 2018 - 2023
9.3 Forecast Market Growth, 2023 - 2028, 2033F Value ($ Million)
- 9.3.1 Market Drivers 2023 - 2028
- 9.3.2 Market Restraints 2023 - 2028

10 Global Cancer Biomarker Market Segmentation

10.1 Global Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
10.2 Global Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
10.3 Global Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
10.4 Global Cancer Biomarker Market, Segmentation By Cancer Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

11 Cancer Biomarker Market, Regional and Country Analysis

11.1 Global Cancer Biomarker Market, By Region, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
11.2 Global Cancer Biomarker Market, By Country, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

12 Asia-Pacific Market

12.1 Summary
12.2 Market Overview
- 12.2.1 Region Information
- 12.2.2 Market Information
- 12.2.3 Background Information
- 12.2.4 Government Initiatives
- 12.2.5 Regulations
- 12.2.6 Regulatory Bodies
- 12.2.7 Major Associations
- 12.2.8 Taxes Levied
- 12.2.9 Corporate Tax Structure
- 12.2.10 Investments
- 12.2.11 Major Companies
12.3 Asia-Pacific Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.4 Asia-Pacific Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.5 Asia-Pacific Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.6 Asia-Pacific Cancer Biomarker Market: Country Analysis
12.7 China Market
12.8 Summary
12.9 Market Overview
- 12.9.1 Country Information
- 12.9.2 Market Information
- 12.9.3 Background Information
- 12.9.4 Government Initiatives
- 12.9.5 Regulations
- 12.9.6 Regulatory Bodies
- 12.9.7 Major Associations
- 12.9.8 Taxes Levied
- 12.9.9 Corporate Tax Structure
- 12.9.10 Investments
- 12.9.11 Major Companies
12.10 China Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.11 China Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.12 China Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.13 India Market
12.14 India Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.15 India Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.16 India Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.17 Japan Market
12.18 Japan Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.19 Japan Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.20 Japan Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.21 Australia Market
12.22 Australia Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.23 Australia Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.24 Australia Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.25 Indonesia Market
12.26 Indonesia Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.27 Indonesia Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.28 Indonesia Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.29 South Korea Market
12.30 South Korea Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.31 South Korea Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.32 South Korea Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

13 Western Europe Market

13.1 Summary
13.2 Market Overview
- 13.2.1 Region Information
- 13.2.2 Market Information
- 13.2.3 Background Information
- 13.2.4 Government Initiatives
- 13.2.5 Regulations
- 13.2.6 Regulatory Bodies
- 13.2.7 Major Associations
- 13.2.8 Taxes Levied
- 13.2.9 Corporate Tax Structure
- 13.2.10 Investments
- 13.2.11 Major Companies
13.3 Western Europe Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.4 Western Europe Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.5 Western Europe Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.6 Western Europe Cancer Biomarker Market: Country Analysis
13.7 UK Market
13.8 UK Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.9 UK Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.10 UK Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.11 Germany Market
13.12 Germany Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.13 Germany Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.14 Germany Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.15 France Market
13.16 France Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.17 France Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.18 France Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.19 Italy Market
13.20 Italy Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.21 Italy Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.22 Italy Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.23 Spain Market
13.24 Spain Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.25 Spain Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.26 Spain Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

14 Eastern Europe Market

14.1 Summary
14.2 Market Overview
- 14.2.1 Region Information
- 14.2.2 Market Information
- 14.2.3 Background Information
- 14.2.4 Government Initiatives
- 14.2.5 Regulations
- 14.2.6 Regulatory Bodies
- 14.2.7 Major Associations
- 14.2.8 Taxes Levied
- 14.2.9 Corporate Tax Structure
- 14.2.10 Investments
- 14.2.11 Major Companies
14.3 Eastern Europe Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.4 Eastern Europe Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.5 Eastern Europe Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.6 Eastern Europe Cancer Biomarker Market: Country Analysis
14.7 Russia Market
14.8 Russia Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.9 Russia Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.10 Russia Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

15 North America Market

15.1 Summary
15.2 Market Overview
- 15.2.1 Region Information
- 15.2.2 Market Information
- 15.2.3 Background Information
- 15.2.4 Government Initiatives
- 15.2.5 Regulations
- 15.2.6 Regulatory Bodies
- 15.2.7 Major Associations
- 15.2.8 Taxes Levied
- 15.2.9 Corporate Tax Structure
- 15.2.10 Investments
- 15.2.11 Major Companies
15.3 North America Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.4 North America Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.5 North America Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.6 North America Cancer Biomarker Market: Country Analysis
15.7 USA Market
15.8 Summary
15.9 Market Overview
- 15.9.1 Country Information
- 15.9.2 Market Information
- 15.9.3 Background Information
- 15.9.4 Government Initiatives
- 15.9.5 Regulations
- 15.9.6 Regulatory Bodies
- 15.9.7 Major Associations
- 15.9.8 Taxes Levied
- 15.9.9 Corporate Tax Structure
- 15.9.10 Investments
- 15.9.11 Major Companies
15.10 USA Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.11 USA Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.12 USA Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.13 Canada Market
15.14 Canada Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.15 Canada Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.16 Canada Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

16 South America Market

16.1 Summary
16.2 Market Overview
- 16.2.1 Region Information
- 16.2.2 Market Information
- 16.2.3 Background Information
- 16.2.4 Government Initiatives
- 16.2.5 Regulations
- 16.2.6 Regulatory Bodies
- 16.2.7 Major Associations
- 16.2.8 Taxes Levied
- 16.2.9 Corporate Tax Structure
- 16.2.10 Investments
- 16.2.11 Major Companies
16.3 South America Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.4 South America Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.5 South America Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.6 South America Cancer Biomarker Market: Country Analysis
16.7 Brazil Market
16.8 Brazil Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.9 Brazil Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.10 Brazil Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

17 Middle East Market

17.1 Summary
17.2 Market Overview
- 17.2.1 Region Information
- 17.2.2 Market Information
- 17.2.3 Background Information
- 17.2.4 Government Initiatives
- 17.2.5 Regulations
- 17.2.6 Regulatory Bodies
- 17.2.7 Major Associations
- 17.2.8 Taxes Levied
- 17.2.9 Corporate Tax Structure
- 17.2.10 Investments
- 17.2.11 Major Companies
17.3 Middle East Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
17.4 Middle East Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
17.5 Middle East Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

18 Africa Market

18.1 Summary
18.2 Market Overview
- 18.2.1 Region Information
- 18.2.2 Market Information
- 18.2.3 Background Information
- 18.2.4 Government Initiatives
- 18.2.5 Regulations
- 18.2.6 Regulatory Bodies
- 18.2.7 Major Associations
- 18.2.8 Taxes Levied
- 18.2.9 Corporate Tax Structure
- 18.2.10 Investments
- 18.2.11 Major Companies
18.3 Africa Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
18.4 Africa Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
18.5 Africa Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

19 Competitive Landscape and Company Profiles

19.1 Company Profiles
19.2 Roche Diagnostics
- 19.2.1 Company Overview
- 19.2.2 Products And Services
- 19.2.3 Business Strategy
- 19.2.4 Financial Overview
19.3 Novartis AG
- 19.3.1 Company Overview
- 19.3.2 Products And Services
- 19.3.3 Business Strategy
- 19.3.4 Financial Performance
19.4 Illumina Inc.
- 19.4.1 Company Overview
- 19.4.2 Products And Services
- 19.4.3 Business Strategy
- 19.4.4 Financial Overview
19.5 Hologic Inc
- 19.5.1 Company Overview
- 19.5.2 Products And Services
- 19.5.3 Business Strategy
- 19.5.4 Financial Overview
19.6 Thermo Fisher Scientific Inc.
- 19.6.1 Company Overview
- 19.6.2 Products And Services
- 19.6.3 Business Strategy
- 19.6.4 Financial performance

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

22.1 Novartis Acquired MorphoSys
22.2 Bristol Myers Squibb Acquired Mirati Therapeutics
22.3 Agilent Acquired Avida Biomed
22.4 Quest Diagnostics Acquired Haystack Oncology
22.5 Prenetics Global Acquired ACT Genomics
22.6 Biocare Medical Acquired Empire Genomics
22.7 Agilent Acquired Resolution Bioscience
22.8 Hologic Acquired Biotheranostics

23 Opportunities And Strategies

23.1 Global Cancer Biomarker Market In 2028 - Countries Offering Most New Opportunities
23.2 Global Cancer Biomarker Market In 2028 - Segments Offering Most New Opportunities
23.3 Global Cancer Biomarker Market In 2028 - Growth Strategies
- 23.3.1 Market Trend Based Strategies
- 23.3.2 Competitor Strategies

24 Cancer Biomarker Market, Conclusions And Recommendations

24.1 Conclusions
24.2 Recommendations
- 24.2.1 Product
- 24.2.2 Place
- 24.2.3 Price
- 24.2.4 Promotion
- 24.2.5 People

25 Appendix

25.1 Geographies Covered
25.2 Market Data Sources
25.3 Research Methodology
25.4 Currencies
25.5 The Business Research Company
25.6 Copyright and Disclaimer